News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Vaxil Reports Promising Results From Its Follow-Up Clinical Trial of ImMucin in Multiple Myeloma a Patients
6/18/2013 10:53:14 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Ness Ziona, 18th June 2013. Vaxil Bio (TASE: VAXL) which is developing therapeutic vaccines
to treat cancer and infectious diseases, reports promising results that were observed in its
follow-up study VAXIL-002 on multiple myeloma patients. Four out of the five patients
enrolled in the study are still in a remission from their illness and have been so for a period
of between 12 and 26 months following completion of their treatment with ImMucin, the
company's therapeutic vaccine. The fifth patient was in a period of remission of 13 months
following completion of his treatment with ImMucin until the disease returned and he was
taken out of the study. Monitoring of these patients is being carried out at Hadassah
Medical Center, Jerusalem and the patients are not receiving any other treatments.
These results will be presented by Dr. Lior Carmon in the IATI-BIOMED conference which is
taking place this week in Tel Aviv.
In April 2013, Vaxil reported on its success in meeting all the endpoints of the clinical trial
VAXIL-001 on 15 patients with multiple myeloma (a bone marrow cancer). All the patients
enrolled in this study were experiencing a gradual re-emergence of the disease after a
period of remission that had been attained by an autologous stem cell transplantation. The
results demonstrated a high safety profile for ImMucin. In addition, 100% of the patients
demonstrated a strong immunological response to ImMucin. Furthermore, nine of the 15
patients demonstrated a clinical response. Of these, five patients ended the study in a state
of Complete Response and a further four ended the study with Stable Disease, which
required no further treatment.
Please view this animated film which explains how Vaxil's therapeutic vaccine ImMucin
Vaxil is an Israeli clinical stage biotechnology company developing therapeutic vaccines to
treat cancer and infectious diseases. The company's vaccines are based on its proprietary
technology, VaxHit, which identifies vaccine candidates (Signal peptide domains) with the
ability to create a specific, strong and promiscuous reaction in various immune system types
(PAN-HLA). As opposed to traditional prophylactic vaccines which protect healthy people
from disease, a therapeutic vaccine takes sick people and seeks to educate their immune
system to identify and destroy cancer cells (or pathogens in the case of infectious diseases)
in a safe, efficient and focused manner, typically with far fewer side effects than other
cancer treatments. From the patient’s perspective a therapeutic vaccine is a drug.
Vaxil’s lead product, ImMucin, teaches the patient’s immune system to identify and destroy
cells which display a specific domain from the cancer marker MUC1 (which appears on 90%
of all cancers). In 2013, Vaxil completed a Phase I/II clinical study with ImMucin on multiple
myeloma patients. The study succeeded in meeting all endpoints. Vaxil is currently planning
a Phase II study using ImMucin in multiple myeloma and a further study in a solid tumor (e.g.
lung or breast cancer.
Vaxil is also developing MTBuVax, a therapeutic vaccine for tuberculosis (“TB”). Globally, TB
is one of the largest causes of mortality. Although most TB cases occur in developing
countries, over the last few years, there has been an increase in incidence rates in the
western world due to the low efficacy of the current TB vaccine (BCG), increased global
travel movements, the mutation of the TB bacteria to new strains which are resistant to drug
treatment and a strong link of TB with HIV infection. MTBuVax is in pre-clinical studies.
Vaxil was founded in 2006 by Dr. Lior Carmon, an expert in cancer immunotherapy, who
holds a PhD from the Weizmann Institute in tumor immunology, and Julian Levy, a seasoned
biotechnology entrepreneur who holds an MA from Cambridge University in Law. The two
have considerable experience founding and running bio-tech projects.
For further details please visit the company's website at www.vaxilbio.com
Help employers find you! Check out all the jobs and post your resume.